Investigating Drug Treatment Costs and Patient Characteristics of Female Breast, Cervical, Colorectal, and Prostate Cancers in Antigua and Barbuda: A Retrospective Data Study (2017-2021)
- PMID: 40566356
- PMCID: PMC12193607
- DOI: 10.3390/ijerph22060930
Investigating Drug Treatment Costs and Patient Characteristics of Female Breast, Cervical, Colorectal, and Prostate Cancers in Antigua and Barbuda: A Retrospective Data Study (2017-2021)
Abstract
Cancers are problematic for health systems globally, including in Antigua and Barbuda, where understanding the changing extent of common cancers is key to implementing effective prevention and control strategies. This study aimed to assess the relationship between treatment rates and drug treatment costs along with characteristics affecting these costs for patients with female breast, cervical, colorectal and prostate cancers in Antigua and Barbuda from 2017 to 2021. A retrospective observational study design was used. Estimates of age-standardized treatment rates and drug treatment costs were determined using direct standardization and a micro-costing approach, respectively. Linear regression was used to evaluate the relationship between age-standardized treatment rates and drug treatment costs. Model independent variables were assessed for multicollinearity and residuals examined for variance and normality. With a sum of 242 cases identified for this study, each cancer type showed evidence of strong positive correlations and significant associations between treatment costs and age-standardized treatment rates. The mean cost (USD) of drug treatment was highest for female breast (USD 25,009.63) and colorectal (USD 13,317.16) cancers and lowest for prostate (USD 12,528.10) and cervical (USD 5121.41) cancers, with several variables showing significance in the respective final models. An association existed between age-standardized treatment rates and drug treatment costs for the cancers studied. These results offer a basis for encouraging strategies in obtaining affordably priced cancer medicines in Antigua and Barbuda.
Keywords: Antigua and Barbuda; breast cancer; cancer; cervical cancer; characteristics; colorectal cancer; costs; drug; prostate cancer; treatment.
Conflict of interest statement
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures


Similar articles
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Incidence, trends and patterns of female breast, cervical, colorectal and prostate cancers in Antigua and Barbuda, 2017-2021: a retrospective study.BMC Cancer. 2025 Jan 13;25(1):72. doi: 10.1186/s12885-025-13459-8. BMC Cancer. 2025. PMID: 39806280 Free PMC article.
-
Interventions for promoting habitual exercise in people living with and beyond cancer.Cochrane Database Syst Rev. 2018 Sep 19;9(9):CD010192. doi: 10.1002/14651858.CD010192.pub3. Cochrane Database Syst Rev. 2018. PMID: 30229557 Free PMC article.
-
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. doi: 10.3310/hta12150. Health Technol Assess. 2008. PMID: 18462574
-
Selenium for preventing cancer.Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD005195. doi: 10.1002/14651858.CD005195.pub4. Cochrane Database Syst Rev. 2018. PMID: 29376219 Free PMC article.
References
-
- Simon L., Gaskin P., Daniel G., Samuel J., Goodwin S. Antigua/Barbuda Cancer Incidence Study. WIMJ Open. 2014;1:84–87. doi: 10.7727/wimjopen.2014.072. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical